NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

October 20, 2023

Study Completion Date

April 23, 2026

Conditions

Atopic Dermatitis

Interventions

DRUG

Tralokinumab

A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.

Trial Locations (11)

11009

LEO Pharma Investigational Site, Cadiz

51100

LEO Pharma Investigational Site, Reims

625 00

LEO Pharma Investigational Site, Brno

150 06

LEO Pharma Investigational Site, Prague

3011 TG

LEO Pharma Investigational Site, Rotterdam

3584 CX

LEO Pharma Investigational Site, Utrecht

08950

LEO Pharma Investigational Site, Esplugues de Llobregat

03010

LEO Pharma Investigational Site, Alicante

M13 9WL

LEO Pharma Investigational Site, Manchester

SE1 9RT

LEO Pharma Investigational Site, London

S10 2TH

LEO Pharma Investigational Site, Sheffield